FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of Formula (II), in which R2a is methyl, ethyl, methoxy, trifluoromethoxy, cyclopropyloxy, C3-C6 alkoxy, ethoxy, –OCH2CH2OCH3, –OCH2CH2OH, –CH(CH3)2, –OCH2CH(CH3)2 or –OCH2CF3; and R2b is hydrogen. The invention also relates to individual compounds, to a pharmaceutical composition, to a method for inducing a sedative effect and/or anesthesia, to a method for treating disorders associated with gamma-aminobutyric acid (hereinafter – GABA) function, to a method for treating a convulsive seizure, to a method for treating epilepsy or an epileptic condition, to a method for treating depression.
EFFECT: new compounds of Formula (II) are obtained, which have the properties of GABA modulators.
Formula (II)
11 cl, 12 dwg, 4 tbl, 36 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEUROACTIVE STEROIDS AND METHODS OF THEIR USE | 2014 |
|
RU2808166C2 |
| NEUROACTIVE STEROIDS AND METHODS FOR USE THEREOF | 2014 |
|
RU2684103C2 |
| COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKOSIS | 2019 |
|
RU2804709C2 |
| BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND ITS USE | 2020 |
|
RU2800652C2 |
| 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USING THEM | 2014 |
|
RU2700264C2 |
| PYRIDOPYRIMIDINE INHIBITORS CDK2/4/6 | 2017 |
|
RU2726115C1 |
| COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEM | 2018 |
|
RU2810331C2 |
| COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | 2015 |
|
RU2733756C2 |
| 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | 2014 |
|
RU2675855C2 |
| 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF THEIR USE | 2014 |
|
RU2812930C2 |
